Francesco Iannacci , João Medeiros Garcia Alcântara , Martina Marani , Paolo Camesasca , Michele Chen , Fani Sousa , Massimo Morbidelli , Mattia Sponchioni
{"title":"用于寡核苷酸生物制造的海洋细菌 Rhodovulum sulfidophilum 的高密度灌注培养。","authors":"Francesco Iannacci , João Medeiros Garcia Alcântara , Martina Marani , Paolo Camesasca , Michele Chen , Fani Sousa , Massimo Morbidelli , Mattia Sponchioni","doi":"10.1016/j.jbiotec.2024.07.010","DOIUrl":null,"url":null,"abstract":"<div><p>Therapeutic oligonucleotides (ONs) are typically manufactured via solid-phase synthesis, characterized by limited scalability and huge environmental footprint, limiting their availability. Biomanufactured ONs have the potential to reduce the immunogenic side-effects, and to improve the sustainability of their chemical counterparts. <em>Rhodovulum sulfidophilum</em> was demonstrated a valuable host for the extracellular production of recombinant ONs. However, low viable cell densities and product titer were reported so far. In this work, perfusion cell cultures were established for the intensification of ON biomanufacturing. First, the perfusion conditions were simulated in 50 mL spin tubes, selected as a scale-down model of the process, with the aim of optimizing the medium composition and process parameters. This optimization stage led to an increase in the cell density by 44 % compared to the reference medium formulation. In addition, tests at increasing perfusion rates were conducted until achieving the maximum viable cell density (VCD<sub>max</sub>), allowing the determination of the minimum cell-specific perfusion rate (CSPR<sub>min</sub>) required to sustain the cell culture. Intriguingly, we discovered in this system also a maximum CSPR, above which growth inhibition starts. By leveraging this process optimization, we show for the first time the conduction of perfusion cultures of <em>R. sulfidophilum</em> in bench-scale bioreactors. This process development pipeline allowed stable cultures for more than 20 days and the continuous biomanufacturing of ONs, testifying the great potential of perfusion processes.</p></div>","PeriodicalId":15153,"journal":{"name":"Journal of biotechnology","volume":"392 ","pages":"Pages 152-160"},"PeriodicalIF":4.1000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168165624001962/pdfft?md5=b661b5bd1729aa57a79fb7be08d1178e&pid=1-s2.0-S0168165624001962-main.pdf","citationCount":"0","resultStr":"{\"title\":\"High-density perfusion cultures of the marine bacterium Rhodovulum sulfidophilum for the biomanufacturing of oligonucleotides\",\"authors\":\"Francesco Iannacci , João Medeiros Garcia Alcântara , Martina Marani , Paolo Camesasca , Michele Chen , Fani Sousa , Massimo Morbidelli , Mattia Sponchioni\",\"doi\":\"10.1016/j.jbiotec.2024.07.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Therapeutic oligonucleotides (ONs) are typically manufactured via solid-phase synthesis, characterized by limited scalability and huge environmental footprint, limiting their availability. Biomanufactured ONs have the potential to reduce the immunogenic side-effects, and to improve the sustainability of their chemical counterparts. <em>Rhodovulum sulfidophilum</em> was demonstrated a valuable host for the extracellular production of recombinant ONs. However, low viable cell densities and product titer were reported so far. In this work, perfusion cell cultures were established for the intensification of ON biomanufacturing. First, the perfusion conditions were simulated in 50 mL spin tubes, selected as a scale-down model of the process, with the aim of optimizing the medium composition and process parameters. This optimization stage led to an increase in the cell density by 44 % compared to the reference medium formulation. In addition, tests at increasing perfusion rates were conducted until achieving the maximum viable cell density (VCD<sub>max</sub>), allowing the determination of the minimum cell-specific perfusion rate (CSPR<sub>min</sub>) required to sustain the cell culture. Intriguingly, we discovered in this system also a maximum CSPR, above which growth inhibition starts. By leveraging this process optimization, we show for the first time the conduction of perfusion cultures of <em>R. sulfidophilum</em> in bench-scale bioreactors. This process development pipeline allowed stable cultures for more than 20 days and the continuous biomanufacturing of ONs, testifying the great potential of perfusion processes.</p></div>\",\"PeriodicalId\":15153,\"journal\":{\"name\":\"Journal of biotechnology\",\"volume\":\"392 \",\"pages\":\"Pages 152-160\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0168165624001962/pdfft?md5=b661b5bd1729aa57a79fb7be08d1178e&pid=1-s2.0-S0168165624001962-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168165624001962\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168165624001962","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
治疗性寡核苷酸(ONs)通常通过固相合成法制造,其特点是可扩展性有限且对环境影响巨大,从而限制了其可用性。生物制造的寡核苷酸有可能减少免疫原性副作用,并提高其化学对应物的可持续性。实验证明,嗜硫红藻是细胞外生产重组 ONs 的重要宿主。然而,迄今为止所报道的可存活细胞密度和产品滴度都很低。在这项工作中,建立了灌注细胞培养物,用于强化ON的生物制造。首先,在 50 毫升旋管中模拟灌注条件,选择 50 毫升旋管作为工艺的缩小模型,目的是优化培养基成分和工艺参数。在这一优化阶段,细胞密度比参考培养基配方提高了 44%。此外,我们还进行了增加灌注速率的测试,直至达到最大存活细胞密度(VCDmax),从而确定了维持细胞培养所需的最小细胞特定灌注速率(CSPRmin)。有趣的是,我们在该系统中还发现了一个最大 CSPR,超过该值就会开始抑制生长。通过利用这一工艺优化,我们首次展示了在台式生物反应器中进行嗜硫杆菌灌流培养的过程。这一工艺开发管道可使培养物稳定生长 20 多天,并可连续进行 ON 生物制造,证明了灌流工艺的巨大潜力。
High-density perfusion cultures of the marine bacterium Rhodovulum sulfidophilum for the biomanufacturing of oligonucleotides
Therapeutic oligonucleotides (ONs) are typically manufactured via solid-phase synthesis, characterized by limited scalability and huge environmental footprint, limiting their availability. Biomanufactured ONs have the potential to reduce the immunogenic side-effects, and to improve the sustainability of their chemical counterparts. Rhodovulum sulfidophilum was demonstrated a valuable host for the extracellular production of recombinant ONs. However, low viable cell densities and product titer were reported so far. In this work, perfusion cell cultures were established for the intensification of ON biomanufacturing. First, the perfusion conditions were simulated in 50 mL spin tubes, selected as a scale-down model of the process, with the aim of optimizing the medium composition and process parameters. This optimization stage led to an increase in the cell density by 44 % compared to the reference medium formulation. In addition, tests at increasing perfusion rates were conducted until achieving the maximum viable cell density (VCDmax), allowing the determination of the minimum cell-specific perfusion rate (CSPRmin) required to sustain the cell culture. Intriguingly, we discovered in this system also a maximum CSPR, above which growth inhibition starts. By leveraging this process optimization, we show for the first time the conduction of perfusion cultures of R. sulfidophilum in bench-scale bioreactors. This process development pipeline allowed stable cultures for more than 20 days and the continuous biomanufacturing of ONs, testifying the great potential of perfusion processes.
期刊介绍:
The Journal of Biotechnology has an open access mirror journal, the Journal of Biotechnology: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
The Journal provides a medium for the rapid publication of both full-length articles and short communications on novel and innovative aspects of biotechnology. The Journal will accept papers ranging from genetic or molecular biological positions to those covering biochemical, chemical or bioprocess engineering aspects as well as computer application of new software concepts, provided that in each case the material is directly relevant to biotechnological systems. Papers presenting information of a multidisciplinary nature that would not be suitable for publication in a journal devoted to a single discipline, are particularly welcome.